Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer
Immunity · 2025-07 · 58 (7) · 1688-1705.e9
DOI: 10.1016/j.immuni.2025.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2025-07. Verfasst von Dig B Mahat und 19 weiteren Autor:innen. Beteiligte Einrichtung: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: mahat@mit.edu. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Suppressor Protein p53, Immune Checkpoint Inhibitors, Chemokine CXCL1. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: mahat@mit.edu.
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.
- Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Cambridge, MA 02139,…
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Ragon Institute of…
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NINDS NIH HHS
- GlaxoSmithKline
- Nile Albright Research Foundation
- Howard Hughes Medical Institute
- National Institutes of Health
- Ragon Institute of MGH, MIT and Harvard
Zitieren
APA
Mahat, D. B., Kumra, H., Castro, S. A., Metcalf, E., Nguyen, K., Morisue, R., Ho, W. W., Chen, I., Sullivan, B., Yim, L. H., Singh, A., Fu, J., Waterton, S. K., Cheng, Y. C., Moiso, E., Chauhan, V. P., Silva, H. M., Spranger, S., Jain, R. K., & Sharp, P. A. (2025). Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer. Immunity, 58(7), 1688-1705.e9. https://doi.org/10.1016/j.immuni.2025.06.005
Vancouver
Mahat DB, Kumra H, Castro SA, Metcalf E, Nguyen K, Morisue R, et al. Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer. Immunity. 2025;58(7):1688-1705.e9. doi:10.1016/j.immuni.2025.06.005
BibTeX
@article{Mahat2025,
author = {Mahat, Dig B and Kumra, Heena and Castro, Sarah A and Metcalf, Emily and Nguyen, Kim and Morisue, Ryo and Ho, William W and Chen, Ivy and Sullivan, Brandon and Yim, Leon H and Singh, Arundeep and Fu, Jiayu and Waterton, Sean K and Cheng, Yu-Chi and Moiso, Enrico and Chauhan, Vikash P and Silva, Hernandez Moura and Spranger, Stefani and Jain, Rakesh K and Sharp, Phillip A},
title = {Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer},
journal = {Immunity},
year = {2025},
volume = {58},
number = {7},
pages = {1688--1705.e9},
doi = {10.1016/j.immuni.2025.06.005}
}
EUVIMED